OTCMKTS:LOGC LogicBio Therapeutics (LOGC) Stock Price, News & Analysis $14.50 +0.05 (+0.35%) As of 10:29 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsShort Interest About LogicBio Therapeutics Stock (OTCMKTS:LOGC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LogicBio Therapeutics alerts:Sign Up Key Stats Today's Range$14.30▼$14.7050-Day Range$8.95▼$14.4552-Week Range$7.05▼$15.05Volume97,259 shsAverage Volume135,654 shsMarket Capitalization$663.09 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview LogicBio Therapeutics was a clinical-stage genetic medicine company focused on developing treatments for rare and serious genetic diseases. The company’s research centered on technologies designed to modify or deliver genetic material directly inside the body. LogicBio’s principal technology platforms included GeneRide, an in vivo gene-insertion approach intended to enable long-term expression of therapeutic genes, and GeneWare, a genome-editing platform. Its lead investigational program, LB-001, was developed as a potential treatment for methylmalonic acidemia, a rare inherited metabolic disorder. Founded in 2014 and headquartered in Cambridge, Massachusetts, LogicBio operated primarily as a biotechnology research and development company serving the rare-disease and genetic-medicine markets. Alexion, AstraZeneca’s rare-disease division, acquired LogicBio in 2022, after which LogicBio ceased operating as an independent publicly traded company.AI Generated. May Contain Errors. Read More LogicBio Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreLOGC MarketRank™: LogicBio Therapeutics scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for LogicBio Therapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of LogicBio Therapeutics is -19.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LogicBio Therapeutics is -19.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLogicBio Therapeutics has a P/B Ratio of 2.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about LogicBio Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.93% of the float of LogicBio Therapeutics has been sold short.Short Interest Ratio / Days to CoverLogicBio Therapeutics has a short interest ratio ("days to cover") of 2.68, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LogicBio Therapeutics has recently decreased by 0.42%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLogicBio Therapeutics does not currently pay a dividend.Dividend GrowthLogicBio Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows3 people have added LogicBio Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LogicBio Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders42.47% of the stock of LogicBio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.05% of the stock of LogicBio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LogicBio Therapeutics' insider trading history. Receive LOGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LOGC Stock News HeadlinesContextLogic Holdings Inc. Publishes Q&A Following Second Quarter 2026 ResultsAugust 21, 2026 | globenewswire.comContextLogic Holdings Inc. Reports Second-Quarter 2026 Financial ResultsAugust 13, 2026 | globenewswire.comWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades near 4,500 dollars today, a 113-to-1 gap between book value and market reality. Treasury Secretary Scott Bessent has said he wants to monetize the asset side of the balance sheet. A revaluation could add more than 1 trillion dollars to the government's books overnight. Certain gold miners still trade as if gold were under 2,000 dollars, even as prices near record highs.September 14 at 1:00 AM | Golden Portfolio (Ad)ContextLogic to Acquire gChem for $850 MillionAugust 5, 2026 | globenewswire.comContextLogic Appoints Seth Siegel as Senior AdvisorJuly 13, 2026 | globenewswire.comContextLogic Holdings Inc. Announces Scott Stewart as Chief Financial Officer & Chief Operating OfficerJune 1, 2026 | globenewswire.comContextLogic Holdings Inc. Publishes Q&A Following First Quarter 2026 ResultsMay 22, 2026 | globenewswire.comContextLogic Holdings Inc. Reports First-Quarter 2026 Financial ResultsMay 15, 2026 | globenewswire.comSee More Headlines LOGC Stock Analysis - Frequently Asked Questions How have LOGC shares performed this year? LogicBio Therapeutics' stock was trading at $7.58 at the start of the year. Since then, LOGC stock has increased by 90.6% and is now trading at $14.45. How were LogicBio Therapeutics' earnings last quarter? LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) posted its quarterly earnings data on Thursday, August, 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.10. The company had revenue of $33.60 million for the quarter, compared to the consensus estimate of $33.60 million. How do I buy shares of LogicBio Therapeutics? Shares of LOGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LogicBio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LogicBio Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), Compass Pathways (CMPS), Ginkgo Bioworks (DNA), Luminar Technologies (LAZR), Toast (TOST) and Globant (GLOB). Company Calendar Last Earnings8/13/2026Today9/14/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:LOGC CIK1664106 Webwww.logicbio.com Phone(617) 245-0399FaxN/AEmployees62Year Founded2014Profitability EPS (Trailing Twelve Months)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29 million Net MarginsN/A Pretax Margin-93.64% Return on Equity-1.21% Return on Assets-0.89% Debt Debt-to-Equity Ratio0.29 Current Ratio1.87 Quick Ratio1.24 Sales & Book Value Annual Sales$43 million Price / Sales15.42 Cash FlowN/A Price / Cash FlowN/A Book Value$4.95 per share Price / Book2.93Miscellaneous Outstanding Shares45,730,000Free Float26,309,000Market Cap$663.09 million OptionableNo Data Beta2.11 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:LOGC) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredGold just passed our debt as the world's #1 assetChina's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | SponsoredPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredWhat is Elon Building in Texas?Elon Musk's latest Texas project is massive - three times the size of Central Park and backed by a reported 12...InvestorPlace | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LogicBio Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
